1,25(OH)2D3 promotes the efficacy of CD28 costimulation blockade by abatacept

Journal of Immunology

Volumn 195, Issue 6, 2015, Pages 2657-2665

  Gardner, David H ^a   Jeffery, Louisa E ^a   Soskic, Blagoje ^b   Briggs, Zoe ^a   Hou, Tie Zheng ^b   Raza, Karim ^a,c   Sansom, David M ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CALCITRIOL; CD28 ANTIGEN; CD3 ANTIGEN; CYCLOSPORIN A; T LYMPHOCYTE RECEPTOR; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; ARTHRITIS, RHEUMATOID; CELL LINE; CELL PROLIFERATION; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE;

ABATACEPT; ANIMALS; ANTIGENS, CD28; APOPTOSIS; ARTHRITIS, RHEUMATOID; CALCITRIOL; CELL LINE; CELL PROLIFERATION; CHO CELLS; CRICETULUS; CYCLOSPORINE; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84941755607     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500306     Document Type: Article

References (61)

1. Morris, G. P., and P. M. Allen. 2012. How the TCR balances sensitivity and specificity for the recognition of self and pathogens. Nat. Immunol. 13: 121-128.
2. Chen, L., and D. B. Flies. 2013. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13: 227-242.
3. Viola, A., and A. Lanzavecchia. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273: 104-106.
4. Noel, P. J., L. H. Boise, J. M. Green, and C. B. Thompson. 1996. CD28 costimulation prevents cell death during primary T cell activation. J. Immunol. 157: 636-642.
5. Thompson, C. B., T. Lindsten, J. A. Ledbetter, S. L. Kunkel, H. A. Young, S. G. Emerson, J. M. Leiden, and C. H. June. 1989. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. USA 86: 1333-1337.
6. Collins, A. V., D. W. Brodie, R. J. C. Gilbert, A. Iaboni, R. Manso-Sancho, B. Walse, D. I. Stuart, P. A. van der Merwe, and S. J. Davis. 2002. The interaction properties of costimulatory molecules revisited. Immunity 17: 201-210.
7. Qureshi, O. S., Y. Zheng, K. Nakamura, K. Attridge, C. Manzotti, E. M. Schmidt, J. Baker, L. E. Jeffery, S. Kaur, Z. Briggs, et al. 2011. Transendocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332: 600-603.
8. Walker, L. S. K., and D. M. Sansom. 2011. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 11: 852-863.
9. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, and A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547.
10. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, and T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985-988.
11. Mandelbrot, D. A., A. J. McAdam, and A. H. Sharpe. 1999. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J. Exp. Med. 189: 435-440.
12. Linsley, P. S., and S. G. Nadler. 2009. The clinical utility of inhibiting CD28-mediated costimulation. Immunol. Rev. 229: 307-321.
13. Buch, M. H., E. M. Vital, and P. Emery. 2008. Abatacept in the treatment of rheumatoid arthritis. Arthritis Res. Ther. 10 (Suppl. 1): S5.
14. Lenschow, D. J., K. C. Herold, L. Rhee, B. Patel, A. Koons, H. Y. Qin, E. Fuchs, B. Singh, C. B. Thompson, and J. A. Bluestone. 1996. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5: 285-293.
15. Riella, L. V., T. Liu, J. Yang, S. Chock, T. Shimizu, B. Mfarrej, I. Batal, X. Xiao, M. H. Sayegh, and A. Chandraker. 2012. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am. J. Transplant. 12: 846-855.
16. Larsen, C. P., T. C. Pearson, A. B. Adams, P. Tso, N. Shirasugi, E. Strobert, D. Anderson, S. Cowan, K. Price, J. Naemura, et al. 2005. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5: 443-453.
17. Kinnear, G., N. D. Jones, and K. J. Wood. 2013. Costimulation blockade: current perspectives and implications for therapy. Transplantation 95: 527-535.
18. Riella, L. V., and M. H. Sayegh. 2013. T-cell co-stimulatory blockade in transplantation: two steps forward one step back! Expert Opin. Biol. Ther. 13: 1557-1568.
19. Jeffery, L. E., A. M. Wood, O. S. Qureshi, T. Z. Hou, D. Gardner, Z. Briggs, S. Kaur, K. Raza, and D. M. Sansom. 2012. Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. J. Immunol. 189: 5155-5164.
20. Penna, G., S. Amuchastegui, N. Giarratana, K. C. Daniel, M. Vulcano, S. Sozzani, and L. Adorini. 2007. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J. Immunol. 178: 145-153.
21. Palmer, M. T., Y. K. Lee, C. L. Maynard, J. R. Oliver, D. D. Bikle, A. M. Jetten, and C. T. Weaver. 2011. Lineage-specific effects of 1,25-dihydroxyvitamin D(3) on the development of effector CD4 T cells. J. Biol. Chem. 286: 997-1004.
22. Zamzami, N., P. Marchetti, M. Castedo, C. Zanin, J. L. Vayssière, P. X. Petit, and G. Kroemer. 1995. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med. 181: 1661-1672.
23. Geginat, J., B. Clissi, M. Moro, P. Dellabona, J. R. Bender, and R. Pardi. 2000. CD28 and LFA-1 contribute to cyclosporin A-resistant T cell growth by stabilizing the IL-2 mRNA through distinct signaling pathways. Eur. J. Immunol. 30: 1136-1144.
24. Peelen, E., S. Knippenberg, A.-H. Muris, M. Thewissen, J. Smolders, J. W. C. Tervaert, R. Hupperts, and J. Damoiseaux. 2011. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun. Rev. 10: 733-743.
25. Bouguermouh, S., G. Fortin, N. Baba, M. Rubio, and M. Sarfati. 2009. CD28 costimulation down regulates Th17 development. PLoS One 4: e5087.
26. Li, H., A. Llera, E. L. Malchiodi, and R. A. Mariuzza. 1999. The structural basis of T cell activation by superantigens. Annu. Rev. Immunol. 17: 435-466.
27. Boomer, J. S., and J. M. Green. 2010. An enigmatic tail of CD28 signaling. Cold Spring Harb. Perspect. Biol. 2: a002436.
28. Acuto, O., and F. Michel. 2003. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat. Rev. Immunol. 3: 939-951.
29. Michel, F., G. Mangino, G. Attal-Bonnefoy, L. Tuosto, A. Alcover, A. Roumier, D. Olive, and O. Acuto. 2000. CD28 utilizes Vav-1 to enhance TCR-proximal signaling and NF-AT activation. J. Immunol. 165: 3820-3829.
30. Michel, F., G. Attal-Bonnefoy, G. Mangino, S. Mise-Omata, and O. Acuto. 2001. CD28 as a molecular amplifier extending TCR ligation and signaling capabilities. Immunity 15: 935-945.
31. Holdorf, A. D., K.-H. Lee, W. R. Burack, P. M. Allen, and A. S. Shaw. 2002. Regulation of Lck activity by CD4 and CD28 in the immunological synapse. Nat. Immunol. 3: 259-264.
32. Riley, J. L., M. Mao, S. Kobayashi, M. Biery, J. Burchard, G. Cavet, B. P. Gregson, C. H. June, and P. S. Linsley. 2002. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc. Natl. Acad. Sci. USA 99: 11790-11795.
33. Diehn, M., A. A. Alizadeh, O. J. Rando, C. L. Liu, K. Stankunas, D. Botstein, G. R. Crabtree, and P. O. Brown. 2002. Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. [Published erratum appears in 2002 Proc Natl. Acad. Sci. USA. 23: 15245.] Proc. Natl. Acad. Sci. USA 99: 11796-11801.
34. Wakamatsu, E., D. Mathis, and C. Benoist. 2013. Convergent and divergent effects of costimulatory molecules in conventional and regulatory CD4+ T cells. Proc. Natl. Acad. Sci. USA 110: 1023-1028.
35. Shahinian, A., K. Pfeffer, K. P. Lee, T. M. Kündig, K. Kishihara, A. Wakeham, K. Kawai, P. S. Ohashi, C. B. Thompson, and T. W. Mak. 1993. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261: 609-612.
36. Kawai, K., A. Shahinian, T. W. Mak, and P. S. Ohashi. 1996. Skin allograft rejection in CD28-deficient mice. Transplantation 61: 352-355.
37. Speiser, D. E., M. F. Bachmann, A. Shahinian, T. W. Mak, and P. S. Ohashi. 1997. Acute graft-versus-host disease without costimulation via CD28. Transplantation 63: 1042-1044.
38. Davis, S. J., and P. A. van der Merwe. 2006. The kinetic-segregation model: TCR triggering and beyond. Nat. Immunol. 7: 803-809.
39. Siefken, R., R. Kurrle, and R. Schwinzer. 1997. CD28-mediated activation of resting human T cells without costimulation of the CD3/TCR complex. Cell. Immunol. 176: 59-65.
40. Tacke, M., G. Hanke, T. Hanke, and T. Hünig. 1997. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur. J. Immunol. 27: 239-247.
41. Lühder, F., Y. Huang, K. M. Dennehy, C. Guntermann, I. Müller, E. Winkler, T. Kerkau, S. Ikemizu, S. J. Davis, T. Hanke, and T. Hünig. 2003. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J. Exp. Med. 197: 955-966.
42. Beyersdorf, N., T. Hanke, T. Kerkau, and T. Hünig. 2005. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann. Rheum. Dis. 64(Suppl. 4): iv91-iv95.
43. June, C. H., J. A. Ledbetter, M. M. Gillespie, T. Lindsten, and C. B. Thompson. 1987. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol. Cell. Biol. 7: 4472-4481.
44. Bolling, S. F., H. Lin, R.-Q. Wei, P. Linsley, and L. A. Turka. 1994. The effect of combination cyclosporine and CTLA4-Ig therapy on cardiac allograft survival. J. Surg. Res. 57: 60-64.
45. Van Gool, S. W., J. L. Ceuppens, H. Walter, and M. de Boer. 1994. Synergy between cyclosporin A and a monoclonal antibody to B7 in blocking alloantigen-induced T-cell activation. Blood 83: 176-183.
46. Perico, N., O. Imberti, M. Bontempelli, and G. Remuzzi. 1995. Toward novel antirejection strategies: in vivo immunosuppressive properties of CTLA4Ig. Kidney Int. 47: 241-246.
47. Ossevoort, M. A., K. Lorré, L. Boon, Y. van den Hout, M. de Boer, P. De Waele, M. Jonker, and A. VandeVoorde. 1999. Prolonged skin graft survival by administration of anti-CD80 monoclonal antibody with cyclosporin A. J. Immunother. 22: 381-389.
48. Liu, E. H., R. M. Siegel, D. M. Harlan, and J. J. O'Shea. 2007. T cell-directed therapies: lessons learned and future prospects. Nat. Immunol. 8: 25-30.
49. Samuel, S., and M. D. Sitrin. 2008. Vitamin D's role in cell proliferation and differentiation. Nutr. Rev. 66(Suppl. 2): S116-S124.
50. Rigby, W. F., T. Stacy, and M. W. Fanger. 1984. Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J. Clin. Invest. 74: 1451-1455.
51. Tsoukas, C. D., D. M. Provvedini, and S. C. Manolagas. 1984. 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. Science 224: 1438-1440.
52. Vanham, G., J. L. Ceuppens, and R. Bouillon. 1989. T lymphocytes and their CD4 subset are direct targets for the inhibitory effect of calcitriol. Cell. Immunol. 124: 320-333.
53. Reichel, H., H. P. Koeffler, A. Tobler, and A. W. Norman. 1987. 1 a,25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc. Natl. Acad. Sci. USA 84: 3385-3389.
54. Lemire, J. M., D. C. Archer, L. Beck, and H. L. Spiegelberg. 1995. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J. Nutr. 125: 1704S-1708S.
55. Jeffery, L. E., F. Burke, M. Mura, Y. Zheng, O. S. Qureshi, M. Hewison, L. S. K. Walker, D. A. Lammas, K. Raza, and D. M. Sansom. 2009. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J. Immunol. 183: 5458-5467.
56. Colin, E. M., P. S. Asmawidjaja, J. P. van Hamburg, A. M. C. Mus, M. van Driel, J. M. W. Hazes, J. P. T. M. van Leeuwen, and E. Lubberts. 2010. 1,25-Dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum. 62: 132-142.
57. Boonstra, A., F. J. Barrat, C. Crain, V. L. Heath, H. F. Savelkoul, and A. O'Garra. 2001. 1a,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J. Immunol. 167: 4974-4980.
58. Tao, X., S. Constant, P. Jorritsma, and K. Bottomly. 1997. Strength of TCR signal determines the costimulatory requirements for Th1 and Th2 CD4+ T cell differentiation. J. Immunol. 159: 5956-5963.
59. Gabrysová, L., J. R. Christensen, X. Wu, A. Kissenpfennig, B. Malissen, and A. O'Garra. 2011. Integrated T-cell receptor and costimulatory signals determine TGF-b-dependent differentiation and maintenance of Foxp3+ regulatory T cells. Eur. J. Immunol. 41: 1242-1248.
60. Sansom, D. M., and L. S. K. Walker. 2013. CD28 costimulation: walking the immunological tightrope. Eur. J. Immunol. 43: 42-45.
61. Gregersen, P. K., H.-S. Lee, F. Batliwalla, and A. B. Begovich. 2006. PTPN22: setting thresholds for autoimmunity. Semin. Immunol. 18: 214-223.